AZT federal reimbursement
Executive Summary
HHS and members of Congress are discussing additional funding sources to provide AZT to AIDS patients who lack other reimbursement plans, Secretary Bowen told a Sept. 15 briefing. HHS has reportedly talked with Sen. Weicker (R-Conn.). Bowen said he wants "not [to] make it an entitlement program" but simply extend funds for AZT therapy to states for six additional months to allow Congress and states more time to find reimbursement solutions. Congress appropriated $ 30 mil. to states last year in a block grant for AZT therapy. Only one state, California, and the District of Columbia have moved to replace the federal grant, Bowen pointed out. A House-Senate conference committee report on the 1989 HHS Appropriations Bill chides the congressional health committees and the states for not adopting measures to pay for AIDS drugs for patients who otherwise cannot afford to obtain them.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.